malignant tumors
Conditions
Interventions
Diyushengbai group:Diyushengbai
Shengbaikeli group:Shengbaikeli
Sponsors
The First People’s Hospital of Lianyungang
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with solid tumors or hematologic tumors confirmed by histopathology or cytology; 2. Aged 18-80 years, any gender; 3. Developed grade I-II leukopenia (2.0 x 10^9/L = 3 months; 6. Voluntarily participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Individuals known to be allergic to Granule for Increasing White Blood Cells, Diyu Shengbai Tablets, or any of their ingredients. 2. Those with yin deficiency with excessive fire, a tendency to bleed, and pregnant women. 3. Those with severe heart, liver, or kidney dysfunction (e.g., NYHA heart function class III-IV, ALT/AST > 3 times the upper limit of normal, Cr > 2 times the upper limit of normal). 4. Those with active infections or uncontrolled serious comorbidities; those with hematopoietic dysfunction. 5. During the study, those planning to use or who have already used granulocyte colony-stimulating factors (G-CSF/GM-CSF), other Chinese or Western medicines for increasing white blood cells (except the study drug). Chinese tonic preparations such as: Shenqi Fuzheng Injection, Zhenqi Fuzheng Granules, Fuzheng Capsules, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood routine ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life score; | — |
Countries
China
Contacts
Public ContactXiaodong Jiang
The First People’s Hospital of Lianyungang
Outcome results
None listed